Tesla Inc is recalling almost 81,000 electric vehicles (EVs) in China — more than it typically ships from its Shanghai factory in any given month — due to a software issue and seat belt problems.
The US EV maker would call back 70,434 imported Model S, Model X and Model 3 vehicles, and 10,127 China-made Model 3 vehicles, the Chinese State Administration for Market Regulation said in a statement yesterday.
The Model S and Model X recalls require an over-the-air software fix to address a defect in the vehicles’ battery management system, which could lead to a loss of power, while the Model 3s have a faulty seat belt fixture.
Photo: AFP
Tesla called for any impacted Model 3 owners to return their cars for a checkup and maintenance if needed, while urging drivers to be “cautious” on the road.
The US electric vehicle maker is going through a rocky patch in China, the world’s biggest automotive market, with deliveries last month falling to 71,704 from a record high of 83,135 in September, underscoring the automaker’s recent price cut to boost demand.
Tesla is changing its marketing approach in China, as fierce competition from domestic rivals such as BYD Co (比亞迪) and uneven sales put its growth plans in what is also the world’s largest EV market at risk.
Although Tesla recently upgraded its Shanghai factory to double capacity to about 1 million cars a year, wait times for cars have shrunk to as little as one week from 22 weeks earlier this year, a sign the company is struggling to boost sales to meet those ambitions.
The company is suffering from other controversies over product safety in China following a recent accident in the southeast of the country that killed two people.
Tesla earlier this month said it would assist a police investigation into the fatal crash involving the Model Y sports utility, but said that data taken from the car showed no proof the brake pedal had been applied.
The driver and his family insisted that the accident must have been caused by a technical problem.
The public was reminded of a protest last year in which a Model 3 owner climbed atop a display vehicle at the Shanghai auto show and yelled that she almost died because her Tesla’s brakes failed.
Tesla, which initially enjoyed a red carpet welcome in China, made a public apology after facing criticism from local authorities and state-run media, without acknowledging any defect to the car.
Yesterday’s recall is not the first for Tesla in China, although its scale is smaller than prior ones.
In June last year, Tesla had to make a software fix to more than 285,000 vehicles, or most of the vehicles it had delivered there in recent years, to address a safety issue identified by the country’s regulator.
China is Tesla’s most important market after the US.
The Model Ys and Model 3s made at its factory on the outskirts of Shanghai supply the local market, and are also exported to other parts of Asia and Europe.
This time was supposed to be different. The memorychip sector, famous for its boom-and-bust cycles, had changed its ways. A combination of more disciplined management and new markets for its products — including 5G technology and cloud services — would ensure that companies delivered more predictable earnings. Yet, less than a year after memory companies made such pronouncements, the US$160 billion industry is suffering one of its worst routs ever. There is a glut of the chips sitting in warehouses, customers are cutting orders and product prices have plunged. “The chip industry thought that suppliers were going to have better control,” said
Enimmune Corp (安特羅生技) has obtained marketing approval from the Food and Drug Administration (FDA) for its EnVAX-A71 vaccine for enterovirus 71 (EV-71), becoming the nation’s first enterovirus vaccine completely made in Taiwan, it said yesterday. After spending 13 years and NT$1.5 billion (US$49.77 million) on the research and development of the vaccine, Enimmune plans to start manufacturing and marketing it by the end of March, the company said in a statement, without disclosing customer order figures. “It is possible that the vaccine would not be included in a national vaccination program initially, and consumers would need to pay for it themselves,” parent
Vaccine skeptics blocking transfusions for life-saving surgeries, Facebook groups inciting violence against doctors and a global search for unvaccinated donors — COVID-19 misinformation has bred a so-called “pure blood” movement. The movement spins anti-vaccine narratives focused on unfounded claims that receiving blood from people inoculated against COVID-19 “contaminates” the body. Some have advocated for blood banks that draw from “pure” unvaccinated people, while medics in North America say they have fielded requests from people demanding transfusions from donors who have not received a vaccine. In closed social media groups, vaccine skeptics — who brand themselves as “pure bloods” — promote violence against doctors
Asteroid mining start-up AstroForge Inc is planning to launch its first two missions to space this year as it seeks to extract and refine metals from deep space. The first launch, scheduled for April, is to test AstroForge’s technique for refining platinum from a sample of asteroid-like material. The second, planned for October, would scout for an asteroid near Earth to mine. The missions are part of AstroForge’s goal of refining platinum-group metals from asteroids, with the aim of bringing down the cost of mining these metals. It also hopes to reduce the massive amount of carbon emissions that stem from mining
RSS